TELA TELA BIO INC revenue, earnings and financials

For the quarter ended June 30, 2026, TELA BIO INC reported revenue of $19.3M (down 4.5% from a year earlier), net income of −$11.3M and diluted EPS of −$0.20; over the last four quarters revenue was $79.9M and net income −$41.1M; for the fiscal year ended December 2025 revenue was $80.3M, up 15.8% on the year before.

TELA annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $80.3M, gross profit $54.3M, operating income −$33.8M, net income −$38.8M (margin -48.3%), EPS −$0.83
• Fiscal year ended Dec 2024: revenue $69.3M, gross profit $46.5M, operating income −$34.1M, net income −$37.8M (margin -54.5%), EPS −$1.33
• Fiscal year ended Dec 2023: revenue $58.5M, gross profit $40.1M, operating income −$44.1M, net income −$46.7M (margin -79.9%), EPS −$2.04
• Fiscal year ended Dec 2022: revenue $41.4M, gross profit $27.0M, operating income −$39.0M, net income −$44.3M (margin -106.9%), EPS −$2.72
• Fiscal year ended Dec 2021: revenue $29.5M, gross profit $18.8M, operating income −$29.5M, net income −$33.3M (margin -112.9%), EPS −$2.30

TELA quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $19.3M (down 4.5% year over year), net income −$11.3M, EPS −$0.20
• Quarter ended Mar 31, 2026: revenue $19.1M (up 2.9% year over year), net income −$12.3M, EPS −$0.21
• Quarter ended Dec 31, 2025 (from the annual report): revenue $20.9M (up 18.2% year over year), net income −$9.01M, EPS −$0.17
• Quarter ended Sep 30, 2025: revenue $20.7M (up 9.1% year over year), net income −$8.60M, EPS −$0.19
• Quarter ended Jun 30, 2025: revenue $20.2M (up 25.5% year over year), net income −$9.92M, EPS −$0.22
• Quarter ended Mar 31, 2025: revenue $18.5M (up 11.5% year over year), net income −$11.3M, EPS −$0.25
• Quarter ended Dec 31, 2024 (from the annual report): revenue $17.6M (up 3.8% year over year), net income −$9.17M, EPS −$0.17
• Quarter ended Sep 30, 2024: revenue $19.0M (up 25.9% year over year), net income −$10.4M, EPS −$0.42
• Quarter ended Jun 30, 2024: revenue $16.1M (up 11.0% year over year), net income −$12.6M, EPS −$0.51
• Quarter ended Mar 31, 2024: revenue $16.6M (up 39.4% year over year), net income −$5.66M, EPS −$0.23
• Quarter ended Dec 31, 2023 (from the annual report): revenue $17.0M (up 46.3% year over year), net income −$12.9M, EPS −$0.50
• Quarter ended Sep 30, 2023: revenue $15.1M (up 34.9% year over year), net income −$11.0M, EPS −$0.45
• Quarter ended Jun 30, 2023: revenue $14.5M (up 39.3% year over year), net income −$10.8M, EPS −$0.46
• Quarter ended Mar 31, 2023: revenue $11.9M (up 44.7% year over year), net income −$12.0M, EPS −$0.63
• Quarter ended Dec 31, 2022 (from the annual report): revenue $11.6M (up 38.8% year over year), net income −$9.98M, EPS −$0.45
• Quarter ended Sep 30, 2022: revenue $11.2M (up 45.8% year over year), net income −$10.7M, EPS −$0.64
• Quarter ended Jun 30, 2022: revenue $10.4M (up 37.7% year over year), net income −$12.7M, EPS −$0.88
• Quarter ended Mar 31, 2022: revenue $8.23M (up 40.1% year over year), net income −$10.9M, EPS −$0.75
• Quarter ended Dec 31, 2021 (from the annual report): revenue $8.37M, net income −$8.62M, EPS −$0.60
• Quarter ended Sep 30, 2021: revenue $7.65M, net income −$8.27M, EPS −$0.57

TELA cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$28.2M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$41.6M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$40.9M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$40.7M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$30.4M, share buybacks n/a

TELA balance sheet

• Jun 30, 2026: cash $30.4M, total assets $59.7M, total liabilities $75.6M, shareholders' equity −$15.9M, long-term debt $56.1M
• Mar 31, 2026: cash $39.5M, total assets $69.9M, total liabilities $75.1M, shareholders' equity −$5.20M, long-term debt $55.9M
• Dec 31, 2025: cash $50.8M, total assets $81.4M, total liabilities $75.1M, shareholders' equity $6.31M, long-term debt $55.7M
• Sep 30, 2025: cash $29.7M, total assets $61.6M, total liabilities $60.0M, shareholders' equity $1.56M, long-term debt $41.5M
• Jun 30, 2025: cash $35.0M, total assets $67.5M, total liabilities $58.4M, shareholders' equity $9.18M, long-term debt $38.1M
• Mar 31, 2025: cash $42.8M, total assets $77.3M, total liabilities $59.1M, shareholders' equity $18.1M, long-term debt $41.3M
• Dec 31, 2024: cash $52.7M, total assets $86.6M, total liabilities $58.1M, shareholders' equity $28.5M, long-term debt $41.1M
• Sep 30, 2024: cash $17.3M, total assets $53.0M, total liabilities $59.3M, shareholders' equity −$6.27M, long-term debt $41.0M

What is TELA's revenue?

TELA BIO INC reported $79.9M of revenue over its last four quarters, through June 30, 2026.

Is TELA profitable?

No. TELA BIO INC lost $41.1M over the last four quarters.

What is TELA's EPS?

Diluted earnings per share over the last four quarters were −$0.77; −$0.20 in the latest quarter.

TELA ownership and insider trades · All stocks